PHESGO® is a subcutaneous combination of pertuzumab and trastuzumab for HER2-positive breast cancer, designed to reduce treatment time.
Related products
Xeloda 500mg x 120Caps (NAFDAC)
Capecitabine
Ozempic 1mg Injection (UK)
Semaglutide

















